These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 20578891)

  • 21. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
    Nozhat Z; Hedayati M
    Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pathogenesis of differentiated thyroid cancer (papillary and follicular)].
    Maciel RM; Kimura ET; Cerutti JM
    Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):691-700. PubMed ID: 16444351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
    Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
    PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
    Smith N; Nucera C
    J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma.
    Pennelli G; Vianello F; Barollo S; Pezzani R; Merante Boschin I; Pelizzo MR; Mantero F; Rugge M; Mian C
    Thyroid; 2011 Dec; 21(12):1393-6. PubMed ID: 22136270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
    Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA
    Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
    Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
    Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin-Drug Conjugate Response.
    Hu H; Ng TSC; Kang M; Scott E; Li R; Quintana JM; Matvey D; Vantaku VR; Weissleder R; Parangi S; Miller MA
    Clin Cancer Res; 2023 Sep; 29(17):3457-3470. PubMed ID: 37289199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
    Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
    Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
    Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
    Ma Y; Qin H; Cui Y
    Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upregulation of the PI3K/Akt pathway in the tumorigenesis of canine thyroid carcinoma.
    Campos M; Kool MM; Daminet S; Ducatelle R; Rutteman G; Kooistra HS; Galac S; Mol JA
    J Vet Intern Med; 2014; 28(6):1814-23. PubMed ID: 25231196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways.
    Li L; Wang X; Sharvan R; Gao J; Qu S
    Biomed Pharmacother; 2017 Nov; 95():1225-1231. PubMed ID: 28931215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.
    Paes JE; Ringel MD
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):375-87, viii-ix. PubMed ID: 18502332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
    Schweppe RE; Kerege AA; Sharma V; Poczobutt JM; Gutierrez-Hartmann A; Grzywa RL; Haugen BR
    Thyroid; 2009 Aug; 19(8):825-35. PubMed ID: 19500021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
    Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
    Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SRY‑related HMG box‑2 role in anaplastic thyroid cancer aggressiveness is related to the fibronectin 1 and PI3K/AKT pathway.
    Wang P; Shang J; Zhao J; Wang K; Guo L; Gu J; Wang W
    Mol Med Rep; 2020 Mar; 21(3):1201-1207. PubMed ID: 31922212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
    Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
    Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.